Skip to content
Compounder
← Superinvestors

Mark Hillman

Net selling

Hillman Capital Management, Inc. — managed by Mark Hillman; US equity positions disclosed quarterly via SEC 13F

Data as of 2026-06-30 (filed 2026-08-14) · Source: SEC EDGAR

Portfolio value$138.2M (−4%)
Holdings54 (−2)
Top holdingCvs Health Corp
Below band5

New

3

Added

14

Exited

5

By what price implies: 24 demand a demanding growth rate, 6 modest.

13F × valuation

Valuation posture

Of 16 valued US positions, 5 trade below a conservative value band (as of 2026-09-03):

SEC 13F · latest filing

Holdings

Showing top 25 of 54 positions

What is a superinvestor

About this investor

Portfolio overview

Hillman Capital Management, Inc.'s most recent 13F filing, for the quarter ended 2026-06-30, reports 54 positions worth $138.2M. The top 5 holdings represent 19% of that value, a broadly diversified portfolio.

The single largest position is Cvs Health Corp at 4.2% of the portfolio, followed by Biogen Inc at 3.8% and Dupont De Nemours Inc at 3.7%.

Against the prior quarter, Mark Hillman opened 3 new positions, exited 5, added to 14, and trimmed 35. The largest new buy was Dupont De Nemours Inc. The most notable sale was the full exit from Dupont De Nemours Inc.

Across all 8 quarters on file, Cvs Health Corp has appeared in every filing, as has Biogen Inc. Cvs Health Corp currently ranks first by value.

A 13F is filed roughly 45 days after quarter-end and covers only long positions in US-listed equities, so it is a lagging and partial view of the portfolio. Source: SEC EDGAR.

Mark Hillman has no positions in the strike zone right now. Browse the whole market by value band

Sources· SEC EDGAR 13F as of 2026-06-30 · filed 2026-08-14

Stay Updated

New-quarter 13F moves and valuation updates, to your inbox.